Article info

Original article
A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

Authors

  1. Correspondence to Professor Paul J Rutgeerts, Department of Medicine, Division of Gastroenterology, University of Leuven, Herestraat 49, 3052 Leuven, Belgium; paul.rutgeerts{at}uz.kuleuven.ac.be
View Full Text

Citation

Rutgeerts PJ, Fedorak RN, Hommes DW, et al
A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

Publication history

  • Revised April 11, 2012
  • Accepted April 12, 2012
  • First published June 20, 2012.
Online issue publication 
July 03, 2013

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.